Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1973 2
1974 1
1975 1
1977 1
1986 1
1988 1
1989 1
1990 1
1992 2
1993 2
1994 2
1995 2
1996 2
1997 7
1998 4
1999 3
2000 3
2003 2
2006 1
2008 2
2009 5
2010 4
2011 6
2012 3
2013 6
2014 6
2015 3
2016 9
2017 5
2018 4
2019 7
2020 12
2021 8
2022 11
2023 10
2024 6
2025 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

137 results

Results by year

Filters applied: . Clear all
Page 1
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).
Wollenberg A, Blauvelt A, Guttman-Yassky E, Worm M, Lynde C, Lacour JP, Spelman L, Katoh N, Saeki H, Poulin Y, Lesiak A, Kircik L, Cho SH, Herranz P, Cork MJ, Peris K, Steffensen LA, Bang B, Kuznetsova A, Jensen TN, Østerdal ML, Simpson EL; ECZTRA 1 and ECZTRA 2 study investigators. Wollenberg A, et al. Among authors: herranz p. Br J Dermatol. 2021 Mar;184(3):437-449. doi: 10.1111/bjd.19574. Epub 2020 Dec 30. Br J Dermatol. 2021. PMID: 33000465 Free PMC article. Clinical Trial.
Effect of invitation to colonoscopy versus faecal immunochemical test screening on colorectal cancer mortality (COLONPREV): a pragmatic, randomised, controlled, non-inferiority trial.
Castells A, Quintero E, Bujanda L, Castán-Cameo S, Cubiella J, Díaz-Tasende J, Lanas Á, Ono A, Serra-Burriel M, Frías-Arrocha E, Hernández C, Jover R, Andreu M, Carballo F, Morillas JD, Salas D, Almazán R, Alonso-Abreu I, Banales JM, Hernández V, Portillo I, Vanaclocha-Espí M, de la Vega M; COLONPREV study investigators. Castells A, et al. Lancet. 2025 Apr 12;405(10486):1231-1239. doi: 10.1016/S0140-6736(25)00145-X. Epub 2025 Mar 27. Lancet. 2025. PMID: 40158525 Clinical Trial.
Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial.
Blauvelt A, Langley RG, Lacour JP, Toth D, Laquer V, Beissert S, Wollenberg A, Herranz P, Pink AE, Peris K, Fangel S, Gjerum L, Corriveau J, Saeki H, Warren RB, Simpson E, Reich K. Blauvelt A, et al. Among authors: herranz p. J Am Acad Dermatol. 2022 Oct;87(4):815-824. doi: 10.1016/j.jaad.2022.07.019. Epub 2022 Jul 19. J Am Acad Dermatol. 2022. PMID: 35863467 Free article.
Drug survival of dupilumab, tralokinumab and upadacitinib in patients with atopic dermatitis: An international, real-world comparative study.
Torres T, Yeung J, Prajapati V, Ribero S, Balato A, Valerio Marzano A, Cruz MJ, Paiva Lopes MJ, Lazaridou E, Carrascosa JM, Alvarenga JM, Farinha P, Duarte B, Sood S, Rankin BD, Ortoncelli M, Caccavale S, Ferrucci SM, Rosa GP, Daponte AI, Silvi G, Peris K, Gori N, Herranz P, Prignano F, Kolios A, Rompoti N, Gkalpakiotis S, Chiricozzi A. Torres T, et al. Among authors: herranz p. J Eur Acad Dermatol Venereol. 2025 Sep;39(9):e756-e761. doi: 10.1111/jdv.20581. Epub 2025 Feb 6. J Eur Acad Dermatol Venereol. 2025. PMID: 39912554 No abstract available.
Lipodystrophy syndromes.
Herranz P, de Lucas R, Pérez-España L, Mayor M. Herranz P, et al. Dermatol Clin. 2008 Oct;26(4):569-78, ix. doi: 10.1016/j.det.2008.05.004. Dermatol Clin. 2008. PMID: 18793991 Free PMC article. Review.
Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study.
Torres T, Yeung J, Prajapati VH, Ribero S, Balato A, Marzano AV, Cruz MJ, Paiva Lopes MJ, Lazaridou E, Carrascosa JM, Alvarenga JM, Farinha P, Duarte B, Munera-Campos M, Sood S, Rankin BD, Ortoncelli M, Caccavale S, Ferrucci SM, Pires Rosa G, Daponte AI, Silvi G, Peris K, Gori N, Prignano F, Kolios A, Herranz P, Gregoriou S, Rompoti N, Gkalpakiotis S, Chiricozzi A. Torres T, et al. Among authors: herranz p. Dermatol Ther (Heidelb). 2025 Aug;15(8):2295-2305. doi: 10.1007/s13555-025-01453-8. Epub 2025 Jun 3. Dermatol Ther (Heidelb). 2025. PMID: 40459711 Free PMC article.
Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening.
Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, Andreu M, Carballo F, Morillas JD, Hernández C, Jover R, Montalvo I, Arenas J, Laredo E, Hernández V, Iglesias F, Cid E, Zubizarreta R, Sala T, Ponce M, Andrés M, Teruel G, Peris A, Roncales MP, Polo-Tomás M, Bessa X, Ferrer-Armengou O, Grau J, Serradesanferm A, Ono A, Cruzado J, Pérez-Riquelme F, Alonso-Abreu I, de la Vega-Prieto M, Reyes-Melian JM, Cacho G, Díaz-Tasende J, Herreros-de-Tejada A, Poves C, Santander C, González-Navarro A; COLONPREV Study Investigators. Quintero E, et al. N Engl J Med. 2012 Feb 23;366(8):697-706. doi: 10.1056/NEJMoa1108895. N Engl J Med. 2012. PMID: 22356323 Free article. Clinical Trial.
Impact of the initial administration of an antiretroviral drug with latency reversal properties on the HIV reservoir size.
De La Torre Tarazona E, Moraga E, Vaquer R, Sánchez-Palomino S, de Lazzari E, Luna L, Vicens-Artés S, García Fraile LJ, Peraire J, Garcia-Gasalla M, Balsalobre L, Guillén Martínez S, López Cortés LF, Jarrín I, Serrano-Villar S, Alcamí J, Moreno S; CoRIS Cohort. De La Torre Tarazona E, et al. Sci Rep. 2025 Jul 13;15(1):25306. doi: 10.1038/s41598-025-09474-1. Sci Rep. 2025. PMID: 40653494 Free PMC article.
Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeks.
Suárez-García I, Alejos B, Moreno C, Martín Torres J, Masiá M, García-Fraile LJ, Riera M, Dalmau D, Rodríguez-Rosado R, Muga R, Moreno S, Jarrín I; CoRIS cohort. Suárez-García I, et al. J Antimicrob Chemother. 2025 Mar 3;80(3):682-691. doi: 10.1093/jac/dkae456. J Antimicrob Chemother. 2025. PMID: 39710424 Free PMC article.
European, multicentre, prospective observational phase IV clinical study to assess the impact of lebrikizumab on health-related well-being and control of skin manifestations in patients with moderate-to-severe atopic dermatitis (ADTrust): study protocol.
Augustin M, Bewley A, Brüggen MC, de Bruin-Weller MS, Ezzedine K, Ferrucci SM, Gkalpakiotis S, Herranz P, Johansson EK, Kampe T, Lapeere H, Legat FJ, Rehbinder EM, Szepietowski JC, Torres T, Vestergaard C, Werfel T, Domenech A, Massana E, Koscielny V, Narayanan S, Kasujee I, Gutermuth J. Augustin M, et al. Among authors: herranz p. BMJ Open. 2025 Jul 11;15(7):e102155. doi: 10.1136/bmjopen-2025-102155. BMJ Open. 2025. PMID: 40645621 Free PMC article.
137 results